Polyamine Oxidase Expression Is Downregulated by 17β-Estradiol via Estrogen Receptor 2 in Human MCF-7 Breast Cancer Cells

Kim, Jin Hyung; Lee, Seung Taek

doi:10.3390/ijms23147521

Cited by 7 publications

(3 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Медиана ВБП на фоне терапии рибоциклибом в группе пациенток люминального В-подтипа РМЖ составила 20,0 ± 3,07 мес. от начала лечения (95% доверительный интервал (ДИ) 13,[9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]. Среднее время до прогрессирования в группе люминального А-подтипа составило 40,4 ± 3,9 мес.…”

Section: выживаемость без прогрессирования в зависимости от гистологи...unclassified

“…В РКП при одинаковых фенотипических характеристиках опухоли отмечаются разные ответы на противоопухолевые препараты. Несмотря на значимые результаты высокой эффективности комбинированной терапии с CDK4/6-ингибиторами при мРМЖ, пациенты в дальнейшем имеют прогрессирование опухолевого процесса, что актуализирует поиск механизмов развития гормонорезистентности как важной онкологической задачи [21][22][23][24][25][26][27]. Первичная и вторичная резистентность, обусловленная обходными сигналами для стимуляции пролиферации опухолевых клеток и способностью к устойчивому формированию комплекса «циклин D -CDK4/6», ограничивает эффективность ингибиторов CDK4/6 [20,21,28].…”

Section: оригинальные исследованияunclassified

See 1 more Smart Citation

The use of ribociclib in real clinical practice: results of a single-center observational retrospective study

Sultanbaev,

Kolyadina,

Musin

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. The standard initial treatment for patients with hormone receptor positive, HER2 negative, metastatic breast cancer (HR+/HER2– mBC) involves the use of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy. The combination therapy has proven effectiveness in numerous Phase II and III randomized controlled trials (RCTs). Nonetheless, RCTs may not fully represent real-world clinical situations due to their stringent inclusion criteria, resulting in a specific patient population.Aim. Analyze of ribociclib using for treating patients with HR+/HER2– advanced breast cancer (mBC) at the Republican Clinical Oncology Dispensary.Materials and methods. Patients diagnosed with HR+/HER2– mBC who were treated in clinical routine with ribociclib in combination with different endocrine agents between 2016 and 2020 were identified and enrolled in this retrospective study. Clinicopathological characteristics and clinical outcomes were recorded with particular emphasis on ribociclib therapy course (progression-free survival (PFS), toxicity, dose reduction).Results. Data from n = 101 patients were evaluated. The mean patient age was 61 years. The study included 67 (66.3%) patients with progression after radical treatment and 34 (33.7%) patients with primary disseminated breast cancer. Dose reduction due to adverse events was performed in n = 14 cases (13.9%). Presence of prior therapy lines and lower ECOG status were associated with shorter PFS, whereas estrogen positivity and the choice of fulvestrant over aromatase inhibitor were positively associated with PFS. Metastatic pattern, progesterone positivity and dose reduction due to toxicity did not significantly impact on PFS.Conclusion. Our real-world data analysis on ribociclib treatment in Russian regional hospital supports data from RCTs regarding both treatment efficacy and safety of CDK4/6i for treatment of patients with HR+/HER2– mBC. Currently, by expanding our experience with CDK4/6 inhibitors in different groups of patients with mBC, we will be able to provide patients with optimal treatment options.

show abstract

Section: выживаемость без прогрессирования в зависимости от гистологи...unclassified

Section: оригинальные исследованияunclassified

The use of ribociclib in real clinical practice: results of a single-center observational retrospective study

Sultanbaev,

Kolyadina,

Musin

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…Total RNA isolation, cDNA synthesis, and RT-PCR proceeded as described [58,59]. The PCR cycling steps were: 94 • C for 30 s (denaturation), optimized annealing temperatures (Supplementary Table S1) for 60 s, and 72 • C for 30 s (extension).…”

Section: Rna Extraction and Rt-pcrmentioning

confidence: 99%

SPARC Is Highly Expressed in Young Skin and Promotes Extracellular Matrix Integrity in Fibroblasts via the TGF-β Signaling Pathway

Ham,

Song,

Yoon

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

The matricellular secreted protein acidic and rich in cysteine (SPARC; also known as osteonectin), is involved in the regulation of extracellular matrix (ECM) synthesis, cell-ECM interactions, and bone mineralization. We found decreased SPARC expression in aged skin. Incubating foreskin fibroblasts with recombinant human SPARC led to increased type I collagen production and decreased matrix metalloproteinase-1 (MMP-1) secretion at the protein and mRNA levels. In a three-dimensional culture of foreskin fibroblasts mimicking the dermis, SPARC significantly increased the synthesis of type I collagen and decreased its degradation. In addition, SPARC also induced receptor-regulated SMAD (R-SMAD) phosphorylation. An inhibitor of transforming growth factor-beta (TGF-β) receptor type 1 reversed the SPARC-induced increase in type I collagen and decrease in MMP-1, and decreased SPARC-induced R-SMAD phosphorylation. Transcriptome analysis revealed that SPARC modulated expression of genes involved in ECM synthesis and regulation in fibroblasts. RT-qPCR confirmed that a subset of differentially expressed genes is induced by SPARC. These results indicated that SPARC enhanced ECM integrity by activating the TGF-β signaling pathway in fibroblasts. We inferred that the decline in SPARC expression in aged skin contributes to process of skin aging by negatively affecting ECM integrity in fibroblasts.

show abstract

Single-cell omics and machine learning integration to develop a polyamine metabolism-based risk score model in breast cancer patients

Zhang,

Guo,

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Breast cancer remains the leading malignant neoplasm among women globally, posing significant challenges in terms of treatment and prognostic evaluation. The metabolic pathway of polyamines is crucial in breast cancer progression, with a strong association to the increased capabilities of tumor cells for proliferation, invasion, and metastasis. Methods We used a multi-omics approach combining bulk RNA sequencing and single-cell RNA sequencing (scRNA-seq) to study polyamine metabolism. Data from The Cancer Genome Atlas, Gene Expression Omnibus, and Genotype-Tissue Expression identified 286 differentially expressed genes linked to polyamine pathways in breast cancer. These genes were analyzed using univariate COX and machine learning algorithms to develop a prognostic scoring algorithm. Single-cell RNA sequencing validated the model by examining gene expression heterogeneity at the cellular level. Results Our single-cell analyses revealed distinct subpopulations with different expressions of genes related to polyamine metabolism, highlighting the heterogeneity of the tumor microenvironment. The SuperPC model (a constructed risk score) demonstrated high accuracy when predicting patient outcomes. The immune profiling and functional enrichment analyses revealed that the genes identified play a crucial role in cell cycle control and immune modulation. Single-cell validation confirmed that polyamine metabolism genes were present in specific cell clusters. This highlights their potential as therapeutic targets. Conclusions This study integrates single cell omics with machine-learning to develop a robust scoring model for breast cancer based on polyamine metabolic pathways. Our findings offer new insights into tumor heterogeneity, and a novel framework to personalize prognosis. Single-cell technologies are being used in this context to enhance our understanding of the complex molecular terrain of breast cancer and support more effective clinical management.

show abstract

Polyamine Oxidase Expression Is Downregulated by 17β-Estradiol via Estrogen Receptor 2 in Human MCF-7 Breast Cancer Cells

Cited by 7 publications

References 71 publications

The use of ribociclib in real clinical practice: results of a single-center observational retrospective study

The use of ribociclib in real clinical practice: results of a single-center observational retrospective study

SPARC Is Highly Expressed in Young Skin and Promotes Extracellular Matrix Integrity in Fibroblasts via the TGF-β Signaling Pathway

Single-cell omics and machine learning integration to develop a polyamine metabolism-based risk score model in breast cancer patients

Contact Info

Product

Resources

About